Global Rabies Prophylaxis Market, By Type (Furious Rabies, Paralytic Rabies, Others), Treatment (Rabies Immunoglobulin, Vaccines, Antiviral drugs, Others), Route of Administration (Oral, Parenteral, Others), End-Users (Hospitals, Specialty Clinics, Homecare, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Others) – Industry Trends and Forecast to 2029
Market Analysis and Size
Rabies is a viral zoonotic disease spread by a dog bite that causes gradual and deadly brain and spinal cord inflammation. Furious rabies and paralytic rabies are the two kinds of rabies. Hyperactivity and hallucination are two symptoms that come with furious rabies. After the onset of particular symptoms such as hydrophobia (fear of water) or aerophobia (fear of flying), rabies is diagnosed in both animals and humans (difficulty in respiration). These late-stage symptoms can be lethal; hence an HRV should be given very away after being bitten by a rabid animal, even if no symptoms are present.
Data Bridge Market Research analyses that the rabies prophylaxis market was valued at USD 910.95 million in 2021 and is expected to reach USD 1226.01 million by 2029, registering a CAGR of 4.20% during the forecast period of 2022 to 2029. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Report Scope and Market Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2022 to 2029
|
|
Base Year
|
2021
|
|
Historic Years
|
2020 (Customizable to 2014 - 2019)
|
|
Quantitative Units
|
Revenue in USD Million, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Type (Furious Rabies, Paralytic Rabies, Others), Treatment (Rabies Immunoglobulin, Vaccines, Antiviral drugs, Others), Route of Administration (Oral, Parenteral, Others), End-Users (Hospitals, Specialty Clinics, Homecare, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Others)
|
|
Countries Covered
|
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
|
|
Market Players Covered
|
F. Hoffmann-La Roche Ltd. (Switzerland), Mylan N.V. (U.S.), Teva Pharmaceutical Industries Ltd. (Ireland), Sanofi (France), Pfizer Inc. (U.S.), GlaxoSmithKline plc (U.K.), Novartis AG (Switzerland), Merck & Co., Inc. (U.S.), Allergan (Ireland), AstraZeneca (U.K.), Johnson & Johnson Private Limited (U.S.), Bristol-Myers Squibb Company (U.S.), Bayer AG (Germany), Dr. Reddy's Laboratories Ltd. (India), Eli Lilly and Company (U.S.), Serum Institute of India Pvt. Ltd. (India), Elanco (U.S.), Virbac (France), Zoetis (U.S.), Cadila Pharmaceuticals (India)
|
|
Market Opportunities
|
|
Market Definition
The rabies virus, which belongs to the family Rhabodoviridae, causes rabies, a serious disease. Rabies is generally a disease that affects animals, but it can also affect humans through bites from dogs, raccoons, cats, foxes, bats, and other mammals. The rabies virus attacks the central nervous system, resulting in brain damage and death. Early rabies symptoms are similar to those of other diseases; however, as the disease progresses, particular symptoms emerge, such as hallucination, sleeplessness, anxiety, paralysis, hyper salivation, hydrophobia, and so on. Rabies can be prevented using an inactivated rabies virus vaccination. The vaccine is only given to patients who are considered to be at high risk. It's also administered to people after they've been exposed to the disease to keep them from getting rabies.
Rabies Prophylaxis Market Dynamics
Drivers
- Increasing investment for healthcare infrastructure
Another significant factor influencing the growth rate of rabies prophylaxis market is the rising healthcare expenditure which helps in improving its infrastructure. Also, various government organizations aim to improve the healthcare infrastructure by increasing funding and this will further influence the market dynamics.
- Rising incidences of rabies
The rising incidences of rabies are expected to flourish themarket's growth rate by increasing the risk of rabies prophylaxis. According to the World Health Organization (WHO), globally, rabies affects approximately 10,000 people per year, according to the World Health Organization (WHO), with dog bites accounting for nearly 99 percent of cases. Rabies symptoms include wounds, fever with pain near the wound, tingling, and pricking at the wound site, and it can lead to cardiac or respiratory collapse if not treated effectively. Rabies claimed the lives of 59,000 people in 150 countries in 2017, with 95 percent of cases occurring in rural areas, according to the World Health Organization (WHO).
Furthermore, rising initiatives by public and private organizations to spread awareness will expand the rabies prophylaxis market. Additionally, increases in number of communities of pet friendly will result in the expansion of rabies prophylaxis market. The rising level of disposable income and increase in demand of vaccine are the major factors anticipated to flourish the market's growth rate during the forecast period of 2022-2029.
Opportunities
- Increase in the number of research and development activities
Moreover, the market's growth is fueled by an increase in the number of research and development activities. This will provide beneficial opportunities for the rabies prophylaxis market growth. For instance, CPL Laboratories (India), a joint venture biotechnology company founded in 2009 by Novavax Inc., USA, and Cadila Pharmaceuticals Limited, announced in 2017 that its Nano- particle vaccine of baculvirous-derived glycoprotein, a four-dose regimen vaccine, is in phase-3 human trials and expected to be approved by 2021. Along with this, rising advancements in pharmaceuticals and biotechnological sectors will further propel the market's growth rate.
Moreover, rising investment for the development of advanced technologies and an increase in the number of emerging markets will provide beneficial opportunities for the rabies prophylaxis market growth during the forecast period.
Restraints/Challenges
On the other hand, the high cost associated with the treatment will obstruct the market's growth rate. The dearth of skilled professionals and lack of healthcare infrastructure in developing economies will challenge the rabies prophylaxis market. Additionally, strict regulatory policies and lack of awareness among people will restrain and further impede the growth rate of the market during the forecast period of 2022-2029.
This rabies prophylaxis market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the rabies prophylaxis market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Patient Epidemiology Analysis
Rabies prophylaxis market also provides you with detailed market analysis for patient analysis, prognosis and cures. Prevalence, incidence, mortality, adherence rates are some of the data variables that are available in the report. Direct or indirect impact analyses of epidemiology to market growth are analysed to create a more robust and cohort multivariate statistical model for forecasting the market in the growth period.
Recent Development
- In April 2022, Cadila Pharmaceuticals Limited announced the launch of novel three-dose recombinant nano-particle based rabies G protein vaccine. Unlike previous regimens, which require five doses spaced over 28 days, it is a three-dose vaccine administered in 50 microgram doses on days 0, 3, and 7. ThRabis is a vaccine produced with Virus-Like Particle technology (VLP).
Global Rabies Prophylaxis Market Scope
The rabies prophylaxis market is segmented on the basis of type, treatment, route of administration, end-users and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Type
- Furious Rabies
- Paralytic Rabies
- Others
Treatment
- Rabies Immunoglobulin
- Vaccines
- Antiviral Drugs
- Others
Route of Administration
- Oral
- Parenteral
- Others
End-Users
- Hospitals
- Specialty Clinics
- Homecare
- Others
Distribution Channel
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
- Others
Rabies Prophylaxis Market Regional Analysis/Insights
The rabies prophylaxis market is analysed and market size insights and trends are provided by country, type, treatment, route of administration, end-users and distribution channel as referenced above.
The countries covered in the rabies prophylaxis market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
North America dominates the rabies prophylaxis market because of the rising prevalence of rabies and increased patient awareness level in this region. Additionally, rising healthcare expenditure and presence of major key players will further propel the market's growth rate in this region.
Asia-Pacific are expected to grow during the forecast period of 2022-2029 due to rise in number of generic manufacturers and surging level of disposable income in this region. Also, the development of healthcare infrastructure and rising government initiatives will further propel themarket's growth rate in this region.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Competitive Landscape and Rabies Prophylaxis Market Share Analysis
The rabies prophylaxis market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to rabies prophylaxis market.
Some of the major players operating in the rabies prophylaxis market are:
- F. Hoffmann-La Roche Ltd. (Switzerland)
- Mylan N.V. (U.S.)
- Teva Pharmaceutical Industries Ltd. (Ireland)
- Sanofi (France)
- Pfizer Inc. (U.S.)
- GlaxoSmithKline plc (U.K.)
- Novartis AG (Switzerland)
- Merck & Co., Inc. (U.S.)
- AstraZeneca (U.K.)
- Johnson & Johnson Private Limited (U.S.)
- Bristol-Myers Squibb Company (U.S.)
- Bayer AG (Germany)
- Dr. Reddy's Laboratories Ltd. (India)
- Eli Lilly and Company (U.S.)
- Serum Institute of India Pvt. Ltd. (India)
- Elanco (U.S.)
- Virbac (France)
- Zoetis (U.S.)
- Cadila Pharmaceuticals (India)
SKU-